Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Jefferson Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc reaffirms FY 2014 revenue guidance; updates FY 2014 EPS guidance to a range above analysts' estimates-Conference Call

Wednesday, 7 May 2014 10:40am EDT 

Biogen Idec Inc:Expects FY 2014 guidance to be in the range of 26 to 28 pct top line growth, and a very similar high 20s percent in terms of bottom line growth.Reported revenue of $6.932 billion and EPS of $8.96 in FY 2013.FY 2014 revenue of $8.838 billion and EPS of $11.50-Thomson Reuters I/B/E/S. 

Company Quote

5.125 +1.53%
24 Dec 2014